Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Nathan Vastesaeger

Correction To: Regional Differences in Baseline Disease Activity and Remission Rates Following Golimumab Treatment for RA: Results From the GO-MORE Trial

Clinical Rheumatology

Medicine

Rheumatology

2018

English

Treatment With Golimumab or Infliximab Reduces Health Resource Utilization and Increases Work Productivity in Patients With Ankylosing Spondylitis in the QUO‐VADIS Study, a Large, Prospective Real‐life Cohort

International Journal of Rheumatic Diseases

Rheumatology

2019

English

Related publications

Sex Differences in the Achievement of Remission and Low Disease Activity in Rheumatoid Arthritis

Arthritis Care and Research

Rheumatology

2020

English

Silent Progression in Patients With Rheumatoid Arthritis: Is DAS28 Remission an Insufficient Goal in RA? Results From the German Remission-Plus Cohort

BMC Musculoskeletal Disorders

English

Reply To: Anti-Carbamylated Protein Antibodies (Anti-CarP) and Higher Baseline Disease Activity in RA, a Replication Study in Three Cohorts

Arthritis and Rheumatology

English

Baseline Differences in the HF-ACTION Trial by Sex

American Heart Journal

Cardiovascular Medicine

Cardiology

2009

English

Letter: Effectiveness of Golimumab to Induce Remission in Outpatient Ulcerative Colitis in Italy

Alimentary Pharmacology and Therapeutics

English

Golimumab for the Treatment of Ulcerative Colitis

Expert Opinion on Biological Therapy

Drug Discovery

Clinical Biochemistry

Pharmacology

2017

English

Anti-Carbamylated Protein Antibodies (Anti-CarP) and Higher Baseline Disease Activity in RA, a Replication Study in Three Cohorts

Arthritis and Rheumatology

English

P146 Golimumab in Rheumatoid and Psoriatic Arthritis. The Relationship Between Minimum Serum Concentration, Anti-Golimumab Antibodies and Activity of Disease

2019

English

Golimumab Administered Subcutaneously Every 4 Weeks in Ankylosing Spondylitis: 104-Week Results of the GO-RAISE Study

Annals of the Rheumatic Diseases

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Nathan Vastesaeger

Correction To: Regional Differences in Baseline Disease Activity and Remission Rates Following Golimumab Treatment for RA: Results From the GO-MORE Trial

Treatment With Golimumab or Infliximab Reduces Health Resource Utilization and Increases Work Productivity in Patients With Ankylosing Spondylitis in the QUO‐VADIS Study, a Large, Prospective Real‐life Cohort

Related publications

Sex Differences in the Achievement of Remission and Low Disease Activity in Rheumatoid Arthritis

Silent Progression in Patients With Rheumatoid Arthritis: Is DAS28 Remission an Insufficient Goal in RA? Results From the German Remission-Plus Cohort

Reply To: Anti-Carbamylated Protein Antibodies (Anti-CarP) and Higher Baseline Disease Activity in RA, a Replication Study in Three Cohorts

Baseline Differences in the HF-ACTION Trial by Sex

Letter: Effectiveness of Golimumab to Induce Remission in Outpatient Ulcerative Colitis in Italy

Golimumab for the Treatment of Ulcerative Colitis

Anti-Carbamylated Protein Antibodies (Anti-CarP) and Higher Baseline Disease Activity in RA, a Replication Study in Three Cohorts

P146 Golimumab in Rheumatoid and Psoriatic Arthritis. The Relationship Between Minimum Serum Concentration, Anti-Golimumab Antibodies and Activity of Disease

Golimumab Administered Subcutaneously Every 4 Weeks in Ankylosing Spondylitis: 104-Week Results of the GO-RAISE Study